|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005508,
umls-concept:C0024554,
umls-concept:C0031327,
umls-concept:C0178602,
umls-concept:C0205171,
umls-concept:C0205344,
umls-concept:C0348016,
umls-concept:C0680730,
umls-concept:C0681850,
umls-concept:C0851347,
umls-concept:C1148554,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2352547,
umls-concept:C2697811,
umls-concept:C2746078,
umls-concept:C2917389
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-11-8
|
|
pubmed:abstractText |
Linagliptin (BI 1356) is a highly specific inhibitor of dipeptidyl peptidase (DPP)-4, which is currently in phase III clinical development for the treatment of type 2 diabetes mellitus. Linagliptin exhibits nonlinear pharmacokinetics after oral administration, which are mainly related to concentration-dependent binding of linagliptin to its target, DPP-4. The objectives of the study were to investigate the pharmacokinetics and pharmacodynamics after intravenous administration of linagliptin and to determine its absolute bioavailability (F).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0312-5963
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
829-40
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21053992-Adolescent,
pubmed-meshheading:21053992-Adult,
pubmed-meshheading:21053992-Area Under Curve,
pubmed-meshheading:21053992-Biological Availability,
pubmed-meshheading:21053992-Cross-Over Studies,
pubmed-meshheading:21053992-Dipeptidyl Peptidase 4,
pubmed-meshheading:21053992-Dipeptidyl-Peptidase IV Inhibitors,
pubmed-meshheading:21053992-Dose-Response Relationship, Drug,
pubmed-meshheading:21053992-Half-Life,
pubmed-meshheading:21053992-Humans,
pubmed-meshheading:21053992-Infusions, Intravenous,
pubmed-meshheading:21053992-Male,
pubmed-meshheading:21053992-Middle Aged,
pubmed-meshheading:21053992-Models, Biological,
pubmed-meshheading:21053992-Protein Binding,
pubmed-meshheading:21053992-Purines,
pubmed-meshheading:21053992-Quinazolines,
pubmed-meshheading:21053992-Single-Blind Method,
pubmed-meshheading:21053992-Tablets,
pubmed-meshheading:21053992-Tissue Distribution,
pubmed-meshheading:21053992-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
|
|
pubmed:affiliation |
Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, Bonn, Germany.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
